{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:07:32Z","timestamp":1789765652511,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Unimolecular dual agonists for the glucagon-like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR) are emerging as a potential new class of important therapeutics in type 2 diabetes (T2D). Reliable and quantitative assessments of in vivo occupancy on each receptor would improve the understanding of the efficacy of this class of drugs. In this study we investigated the target occupancy of the dual agonist SAR425899 at the GLP1R in pancreas and GCGR in liver by Positron Emission Tomography\/Computed Tomography (PET\/CT). Patients with T2D were examined by [<jats:sup>68<\/jats:sup>Ga]Ga-DO3A-Tuna-2 and [<jats:sup>68<\/jats:sup>Ga]Ga-DO3A-Exendin4 by PET, to assess the GCGR in liver and GLP1R in pancreas, respectively. Follow up PET examinations were performed after 17 (GCGR) and 20 (GLP-1R) days of treatment with SAR425899, to assess the occupancy at each receptor. Six out of 13 included patients prematurely discontinued the study due to adverse events. SAR425899 at a dose of 0.2\u00a0mg daily demonstrated an average GCGR occupancy of 11.2\u2009\u00b1\u200914.4% (SD) in N\u2009=\u20095 patients and a GLP1R occupancy of 49.9\u2009\u00b1\u200913.3%. Fasting Plasma Glucose levels (\u2212\u20093.30\u2009\u00b1\u20091.14\u00a0mmol\/L) and body weight (\u2212\u20093.87\u2009\u00b1\u20090.87%) were lowered under treatment with SAR425899. In conclusion, SAR425899 demonstrated strong interactions at the GLP1R, but no clear occupancy at the GCGR. The study demonstrates that quantitative target engagement of dual agonists can be assessed by PET.<\/jats:p>","DOI":"10.1038\/s41598-020-73815-5","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T10:02:46Z","timestamp":1602064966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Receptor occupancy of dual glucagon-like peptide 1\/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-8790","authenticated-orcid":false,"given":"Olof","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Hijazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenore","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iina","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Erik","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Velikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pierrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Tillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"73815_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","volume":"60","author":"MA S\u00e1nchez-Garrido","year":"2017","unstructured":"S\u00e1nchez-Garrido, M. A. et al. GLP-1\/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60, 1851\u20131861 (2017).","journal-title":"Diabetologia"},{"key":"73815_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nchembio.209","volume":"5","author":"JW Day","year":"2009","unstructured":"Day, J. W. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749\u2013757 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"73815_CR3","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/db09-0278","volume":"58","author":"A Pocai","year":"2009","unstructured":"Pocai, A. et al. Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258\u20132266 (2009).","journal-title":"Diabetes"},{"key":"73815_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/hep.28962","volume":"65","author":"MP Valdecantos","year":"2017","unstructured":"Valdecantos, M. P. et al. A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology 65, 950\u2013968 (2017).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"73815_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2337\/db18-78-OR","volume":"67","author":"M Jain","year":"2018","unstructured":"Jain, M. et al. MEDI0382, a GLP\/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes mellitus. Diabetes 67(Suppl. 1), 78 (2018).","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"73815_CR6","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.2337\/db18-1841-P","volume":"67","author":"M Beaton","year":"2018","unstructured":"Beaton, M. et al. MEDI0382, a GLP-1\/glucagon receptor dual agonist, dramatically reduces hepatic collagen in a mouse model of NASH. Diabetes 67(Suppl. 1), 1841 (2018).","journal-title":"Diabetes"},{"key":"73815_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13550-019-0482-0","volume":"9","author":"I Velikyan","year":"2019","unstructured":"Velikyan, I. et al. First-in-class positron emission tomography tracer for the glucagon receptor. EJNMMI Res. 9, 17 (2019).","journal-title":"EJNMMI Res."},{"key":"73815_CR8","doi-asserted-by":"publisher","first-page":"14960","DOI":"10.1038\/s41598-019-51530-0","volume":"9","author":"O Eriksson","year":"2019","unstructured":"Eriksson, O. et al. Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. Sci. Rep. 9, 14960 (2019).","journal-title":"Sci. Rep."},{"key":"73815_CR9","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.2967\/jnumed.112.114066","volume":"54","author":"RK Selvaraju","year":"2013","unstructured":"Selvaraju, R. K. et al. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4. J. Nucl. Med. 54, 1458\u20131463 (2013).","journal-title":"J. Nucl. Med."},{"key":"73815_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00259-014-2745-3","volume":"41","author":"L Nalin","year":"2014","unstructured":"Nalin, L. et al. Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs. Eur. J. Nucl. Med. Mol. Imaging. 41, 1800\u20131810 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"73815_CR11","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1021\/acs.jmedchem.7b00174","volume":"60","author":"A Evers","year":"2017","unstructured":"Evers, A. et al. Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists. J. Med. Chem. 60, 4293\u20134303 (2017).","journal-title":"J. Med. Chem."},{"key":"73815_CR12","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1210\/en.2018-00399","volume":"159","author":"R Elvert","year":"2018","unstructured":"Elvert, R. et al. Team players or opponents: Coadministration of selective glucagon and GLP-1 receptor agonists in obese diabetic monkeys. Endocrinology 159, 3105\u20133119 (2018).","journal-title":"Endocrinology"},{"key":"73815_CR13","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/dom.13212","volume":"20","author":"R Elvert","year":"2018","unstructured":"Elvert, R. et al. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates. Diabetes Obes. Metab. 20, 1836\u20131851 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"73815_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/dom.13494","volume":"21","author":"J Tillner","year":"2019","unstructured":"Tillner, J. et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes. Metab. 21, 120\u2013128 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"73815_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1674-8301(12)60014-1","volume":"26","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. & Fox, G. B. PET imaging for receptor occupancy: Meditations on calculation and simplification. J. Biomed. Res. 26, 69\u201376 (2012).","journal-title":"J. Biomed. Res."},{"key":"73815_CR16","first-page":"111","volume":"7","author":"I Velikyan","year":"2017","unstructured":"Velikyan, I., Rosenstrom, U. & Eriksson, O. Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-exendin-4 for clinical use. Am. J. Nucl. Med. Mol. Imaging. 7, 111\u2013125 (2017).","journal-title":"Am. J. Nucl. Med. Mol. Imaging."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73815-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73815-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:23:22Z","timestamp":1670358202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73815-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73815"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73815-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"3 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Torsten Haack, Youssef Hijazi, Lenore Teichert, Veronique Tavernier, Iina Laitinen, Michael Wagner and Joachim Tillner are employees of Sanofi-Aventis. Olof Eriksson, Stefan Pierrou and Lars Johansson are employees of Antaros Medical AB. Sven Eric Berglund is an employee of CTC AB. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16758"}}